http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112625125-B
Outgoing Links
Predicate | Object |
---|---|
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-52 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13 |
filingDate | 2021-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2021-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2021-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CN-112625125-B |
titleOfInvention | Monoclonal antibody for neutralizing novel coronavirus infection |
abstract | The invention discloses a monoclonal antibody for neutralizing novel coronavirus infection. The invention provides an antibody, wherein the amino acid sequence of a light chain variable region of the antibody is 1 st to 110 th in a sequence 2 in a sequence table; the amino acid sequence of the heavy chain variable region is 1 st to 120 th of the sequence 4 in the sequence table. The invention identifies that the monoclonal antibody N5 has stronger binding specificity and affinity to the S protein RBD (receptor binding domain) of the novel coronavirus, and in vitro neutralization experiments show that N5 can effectively neutralize the infection activity of the novel coronavirus SARS-CoV-2. On the basis, the gene sequence of the N5 antibody is measured and then recombined and expressed, and the expressed recombined antibody also has the activity of neutralizing SARS-CoV-2. |
priorityDate | 2021-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 471.